KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZN) Invested Capital (2016 - 2025)

Historic Invested Capital for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $45.2 billion.

  • Astrazeneca's Invested Capital fell 3644.02% to $45.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $45.2 billion, marking a year-over-year decrease of 3644.02%. This contributed to the annual value of $45.2 billion for FY2025, which is 3644.02% down from last year.
  • Astrazeneca's Invested Capital amounted to $45.2 billion in Q4 2025, which was down 3644.02% from $39.4 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Invested Capital peaked at $71.2 billion during Q4 2024, and registered a low of $14.6 billion during Q1 2021.
  • Its 5-year average for Invested Capital is $41.4 billion, with a median of $38.3 billion in 2023.
  • In the last 5 years, Astrazeneca's Invested Capital soared by 58930.59% in 2021 and then tumbled by 3644.02% in 2025.
  • Over the past 5 years, Astrazeneca's Invested Capital (Quarter) stood at $70.1 billion in 2021, then fell by 5.39% to $66.3 billion in 2022, then increased by 2.26% to $67.8 billion in 2023, then increased by 4.98% to $71.2 billion in 2024, then tumbled by 36.44% to $45.2 billion in 2025.
  • Its Invested Capital was $45.2 billion in Q4 2025, compared to $39.4 billion in Q3 2025 and $44.8 billion in Q2 2025.